• Alias: FK228; FR901228; NSC 630176
    • A bicyclic depsipeptide antibiotic isolated from the bacterium chromobacterium violaceum that binds to and inhibits HDAC, resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. It also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.
    • FDA approved for cutaneous T-cell and PTCL patients who have had one prior systemic chemotherapy.
    • Metabolism: Major CYP3A4 substrate. Avoid grapefruit juice.
    • Recommended dose: 14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 8-day cycle
    Other topics in Targeted and Immunotherapy Agents